Transcriptional Reprogramming of GPCR Signaling Pathways in the Frontal Cortex of Morphine Dependent Mice Authors: Mijin Kim, Sohyeon Moon, Taddesse Yayeh, Thea Villa, Seikwan Oh Published: 2026 ABSTRACT AbstractRepeated morphine administration for managing persistent pain frequently induces both physical and psychological dependence, accompanied by alterations in cortical gene expression. To elucidate the molecular underpinnings of morphine dependence, gene expression in the frontal cortex of mice subjected to acute and chronic morphine treatment was profiled using microarray analysis and validated by semi-quantitative PCR. Genes including Drd2, Adora2a, Olfr767, Egr2, Gng7, and Gpr6 were upregulated following both acute and chronic morphine treatment. Gene ontology analysis revealed significant enrichment of differentially expressed genes in membrane components, GPCR signaling pathways, and neurological system processes, indicating integrated alterations in receptor-mediated signaling and downstream transcriptional regulation. Consistent with this, selective phosphorylation of CREB was observed during naloxone-precipitated withdrawal, highlighting CREB-dependent transcription as a key molecular correlate of cortical neuroadaptation. Behavioral assays confirmed robust physical and psychological dependence, supporting the functional relevance of these molecular changes. Collectively, these findings identify a GPCR-centered molecular framework in which coordinated regulation and functional interaction of receptors such as DRD2 and ADORA2A, along with associated signaling components, contribute to morphine-induced neuroplasticity and dependence. These insights may provide a foundation for the development of targeted therapeutic strategies to mitigate opioid dependence.Keywords: Morphine, Gene expressions, Dopamine receptor, GPCR signaling, CREB, Microarray INTRODUCTION Addiction to psychostimulants poses a significant public health hazard and recently, there are alarmingly rising evidences of gene expression, particularly within the brain's reward regions (Becker et al., 2017; Yazdani et al., 2016). A recent review showed the importance of epigenetic processes in regulating gene expression and clearly figured out the role that dynamic epigenetic changes may play in psychostimulant-induced addiction via long-lasting transcriptional changes following repeated drug exposure (Kalda and Zharkovsky, 2015). Morphine is a potent analgesic but its continual use results in analgesic dependence that may arise from changes in N-methyl-D-aspartate acid receptor subunit 1(NR1) gene expression (Ahmadi et al., 2016; Mohammadi et al., 2016). Moreover, morphine exposure is known to alter gene expression via epigenetic mechanisms, leading to adaptations in neuronal signaling that underlie tolerance and dependence (Blaze et al., 2024; Mendez et al., 2023; Sahbaie et al., 2016). Presumably, the search for newly identified gene expression becomes indispensable for alternative therapeutic options against morphine dependence, including genetic engineering in order to diminish morphine withdrawal syndromes (Li et al., 2022; Panday et al., 2024; Wang et al., 2022). As part of ongoing efforts to reduce the overwhelming morphine withdrawal syndrome, through the use of microarray analysis, various gene expressions from morphine dependent mice were screened. Recent evidence indicates that morphine exposure modulates cortical expression of genes involved in G protein–coupled receptor (GPCR) signaling, including dopamine D2 receptors (DRD2) and adenosine A2A receptors (ADORA2A) (Adhikary et al., 2022; Li et al., 2023). DRD2 and ADORA2A can form heteromeric complexes in neuronal circuits, exerting opposing regulation of intracellular cAMP signaling (Ferré et al., 2018). Activation of ADORA2A stimulates Gs-mediated cAMP production, whereas DRD2 signaling inhibits adenylyl cyclase via Gi/o proteins, suggesting this coordinated regulation may represent an adaptive mechanism to maintain signaling balance during repeated morphine exposure (Babenko et al., 2020; Rao et al., 2025). Alterations in GPCR-mediated signaling can impact downstream transcriptional regulators, particularly cAMP response element-binding protein (CREB). Phosphorylation of CREB is a key step in translating receptor-level signals into activity-dependent gene expression, which contributes to synaptic plasticity and behavioral adaptations associated with opioid tolerance and dependence (Coffey and Neumaier, 2024; Moradi Vastegani et al., 2022; Yi et al., 2025; Yin et al., 2022). The coordinated upregulation of DRD2 and ADORA2A, together with changes in other GPCR-related genes, suggests a broader remodeling of receptor signaling networks that may influence receptor sensitivity, desensitization, and heteromerization, ultimately shaping the neuroplastic and behavioral responses to chronic morphine exposure. Despite these advances, targeted interventions for opioid use disorders remain limited, and the precise molecular mechanisms underlying morphine-induced neuroadaptations are not fully understood. This study aims to address this gap by establishing a morphine-dependent mouse model and systematically exploring potential molecular targets, focusing on GPCR-centered signaling networks including DRD2, ADORA2A, and downstream effectors such as CREB. MATERIALS AND METHODS Animals C57BL/6J male mice (20-23 g) at 7 weeks of age were obtained from Daehan Biolink (Eumsung, Korea). The mice were maintained on 12 h light-dark cycle with a room temperature of 23 ± 3°C. Mice were housed in plastic cages, supplied with water and chow ad libitum, and acclimatized for one week before the experiment. All procedures were performed according to the guidelines approved by the Institutional Animal Care and Use Committee of Ewha Womans University School of Medicine (EWHA MEDIACUC 21-029-2). Morphine treatment for gene expression microarray assays Mice (n=10 per group) were classified into chronic, acute and untreated groups, each of them received i.p injections twice daily at 09:00 h and 18:00 h. Chronic treatment groups were injected with morphine (i.p. 20 mg/kg) twice daily for nine days whereas acute treatment groups were injected with saline twice for 8 days with a final single injection of morphine (i.p. 20 mg/kg) on day nine. Untreated control mice received injections of saline twice daily for nine days. At the end of the experiment, mice were injected with naloxone (5 mg/kg) at 7 h after the final morphine injection, and mice were sacrificed and the cortex was immediately dissected and kept on ice temporarily until it was deep frozen for RNA extraction. Jumping test Mice (n=10 per group) were used for the morphine dependence behavioral study. Morphine was purchased from Myungmoon Pharm (Seoul, Korea) and morphine use and purchase was approved by the Korean Food and Drug Administration. Morphine (20 mg/kg) was administered intraperitoneally twice daily for 9 consecutive days to induce physical dependence (Fig. 1A). On day 10, withdrawal was precipitated by intraperitoneal injection of naloxone (5 mg/kg) on 7 h of the final morphine injection, and withdrawal behavior was assessed by quantifying the number of jumps for 30 min. Morphine withdrawal symptoms were assessed using a modified protocol (Burma et al., 2017; Kohro et al., 2025). Behavioral assessment of morphine-induced physical and psychological dependence. (A) Schematic illustration of the jumping test used to evaluate physical dependence following chronic morphine administration. (B) Schematic illustration of the conditioned place preference (CPP) test used to assess psychological dependence. (C) Number of naloxone-precipitated jumps in morphine-treated and saline control mice. (D) Time spent in the non-preferred (white) chamber during pre- and post-conditioning phases of the CPP test. Data are presented as mean ± SEM; Statistical significance was determined by unpaired two-tailed t-test. ***p<0.001. Condition place preference (CPP) test The conditioned place preference (CPP) apparatus consisted of two transparent acrylic compartments separated by a manually operated guillotine door. Each compartment was identical in size (20×20×25 cm) but differed in contextual cues. One chamber had white walls with a stainless-steel grid floor arranged horizontally, whereas the other chamber had black walls with a stainless-steel grid floor arranged vertically. The apparatus was illuminated at 90 lx during testing. After each session, the entire chamber was thoroughly cleaned with 75% ethanol to eliminate residual olfactory cues. The CPP procedure consisted of four phases: pre-conditioning, pre-test, conditioning, and post-test (Fig. 1B). During the pre-conditioning phase, mice (n=10 per group) in both groups received intraperitoneal saline injections and were allowed to freely explore both compartments with the guillotine door open for 30 min per day for 3 consecutive days. On day 4, following saline injection (i.p.), a 15-min pre-test session was conducted to assess baseline place preference. For CPP acquisition, conditioning sessions were conducted over 9 days using an alternating schedule. On one day, mice received morphine (i.p. 20 mg/kg) and were confined to the white (initially nonpreferred) chamber for 30 min. On the following day, mice received saline (i.p.) and were confined to the black (initially preferred) chamber for 30 min. This alternating pairing was repeated three times. In the control group, mice received saline injections during all conditioning sessions and were confined to the corresponding chambers following the same schedule. Twenty-four hours after the final conditioning session, mice were re-exposed to the CPP apparatus with the guillotine door open and allowed to freely explore both compartments for 15 min (post-test), during which time spent in each chamber was recorded. The CPP test was conducted as previously described, with minor modifications (Gu et al., 2025; McKendrick and Graziane, 2020). Total RNA isolation Total RNA was isolated and purified from mouse cortex using SV Total RNA Isolation System (Promega Co., Madison, WI, USA). The integrity of each RNA sample was determined using Bioanalyzer 2100 Analysis (Agilent Technologies, Santa Clara, CA, USA), and the RNA quality was determined using Nano Drop 8000 Analysis following manufacturer’s instructions. Gene expression microarray assays Total RNA was isolated from mouse cortical tissues and cDNA was synthesized using the WT cDNA Synthesis and Amplification Kit (Affymetrix, Santa Clara, CA, USA). Fragmented and terminal labeled cDNA was hybridized using the Hybridization Control Kit (Affymetrix). The GeneChip Mouse Gene 1.0 ST Arrays (Affymetrix) contain 770,317 oligonucleotide probes, unique 25-mer oligonucleotide probes that interrogate 28,853 estimated number of genes with an average of 27 probes across the full length of each gene. Assistance in RNA quality control, labeling, hybridization, and initial data analysis were provided by DNA Link Inc. (Seoul, Korea). Only those genes with adjusted p values <0.05 were considered for further RT-PCR analysis. Reverse transcriptase polymerase chain reaction (RT-PCR) Total RNA from brain cortex tissue was isolated and then 2 µg of total RNA was reverse-transcribed using the SuperScript First-Stand Synthesis System (Invitrogen, Carlsbad, CA, USA) to prepare cDNA. This was amplified by PCR using primers for Drd2, Adora2a, Penk, Gng2, Olfr767, Tac1, Gpr6, Egr2, Cyr61, Dub2a, and Gapdh. The PCR products were separated by 1% agarose gel electrophoresis. Western blot Cortical tissues were homogenized in RIPA buffer supplemented with protease and phosphatase inhibitors. Protein concentrations were determined using a BCA assay. Equal amounts of protein (20-30 µg) were separated by SDS-PAGE and transferred onto PVDF membranes. Membranes were blocked with 5% non-fat milk in Tris-buffered saline with 0.1% Tween-20 (TBST) for 1 h at room temperature and incubated overnight at 4°C with primary antibodies against GAPDH, Nrf2, HO-1, NQO1, βB1-crystallin, βB2-crystallin, γ-crystallin, HSP70, TH, GAD65/67, CREB, and pCREB. After washing, membranes were incubated with HRP-conjugated secondary antibodies for 1 h at room temperature. Protein bands were visualized using enhanced chemiluminescence and imaged. Each lane corresponds to an independent mouse cortical sample (n=3 per group). Statistical analysis Statistical analysis was performed using Graph Prism 5 software (GraphPad Software Inc., San Diego, CA, USA). Values were expressed as means ± standard error of the mean (SEM), and statistical significance was set at p<0.05. Data were analyzed using an unpaired two-tailed t-test. RESULTS Validation of morphine-induced physical and psychological dependence using jumping and CPP tests Jumping and conditioned place preference (CPP) tests were performed to validate morphine-induced physical and psychological dependence, respectively. Both behavioral paradigms are well-established and widely accepted methods for assessing opioid dependence and reward-related behavior. In the present study, the dose and administration schedule of morphine were carefully optimized to reliably induce dependence. As expected, mice receiving repeated morphine administration exhibited a markedly and significantly higher number of naloxone-precipitated jumps compared with the saline-treated control group, confirming the successful induction of physical dependence (Fig. 1C). Consistent with these findings, the CPP assay demonstrated that morphine-treated mice showed a significant increase in time spent in the white chamber (initially nonpreferred compartment) during the post-test phase, indicating robust drug-associated contextual preference (Fig. 1D). In contrast, control mice did not display significant changes in chamber preference. Collectively, these results confirm that our experimental conditions reliably establish both physical and psychological components of morphine dependence. Furthermore, this validated behavioral model may serve as a useful platform not only for morphine but also for evaluating other opioid compounds and substances with abuse liability. Differential cortical gene expression profiles following acute and chronic morphine administration in mice identified by microarray analysis Repeated morphine administration not only induces behavioral dependence but may also lead to altered gene expression in distinct brain regions. To identify transcriptional changes associated with morphine exposure, microarray analysis was performed. Using microarray profiling, diverse gene expression changes in the frontal cortex of mice following acute and chronic morphine treatment were identified. Several genes were upregulated by two-fold or greater under both acute and chronic conditions, including dopamine receptor D2 (Drd2, NM_010077), adenosine A2a receptor (Adora2a, NM_009630), olfactory receptor 767 (Olfr767, NM_146318), and early growth response 2 (Egr2, NM_010118). In addition, a subset of genes exhibited moderate but consistent increases ranging from 1.5- to 2-fold. This included cysteine rich protein 61 (Cyr61, NM_010516), guanine nucleotide binding protein gamma 7 (Gng7, NM_001038655), preproenkephalin (Penk, NM_001002927), tachykinin 1 (Tac1, NM_009311), delta-like 1 homolog (Dlk1, NM_010052), and G protein-coupled receptor 6 (Gpr6, NM_199058) (Table 1, 2). Table 1Enhanced expression levels of certain genes in the cortex after an acute treatment of morphine (20 mg/kg i.p. on day 9) in miceSymbolDescriptionGene bank acc. No.p-valueFold inductionDRD2dopamine receptor 2NM_0100776.10E-052.18ADORA2Aadenosine A2a receptorNM_0096306.10E-052.27GNG7guanine nucleotide binding protein (G protein), gamma 7NM_0010386553.53E-041.60PENKpreproenkephalinNM_0010029273.53E-041.96OLFR767olfactory receptor 767NM_1463180.0059122.25TAC1tachykinin 1NM_0093110.0059121.78DLK1delta-like 1 homolog (Drosophila)NM_0100520.0325991.52GPR6G protein-coupled receptor 6NM_1990580.0059121.52EGR2early growth response 2NM_0101186.10E-052.23CYR61cysteine rich protein 61NM_0105166.10E-051.68 Enhanced expression levels of certain genes in the cortex after an acute treatment of morphine (20 mg/kg i.p. on day 9) in mice Table 2Enhanced expression levels of certain genes in the cortex after chronic treatment of morphine (morphine 20 mg/kg i.p. twice daily for 9 days) in miceSymbolDescriptionGene bank acc. No.p-valueFold inductionDRD2dopamine receptor 2NM_0100771.59E-054.40ADORA2Aadenosine A2a receptorNM_0096301.59E-052.30GNG7guanine nucleotide binding protein (G protein), gamma 7NM_0010386551.59E-051.50PENKpreproenkephalinNM_0010029271.59E-052.71OLFR767olfactory receptor 767NM_1463181.59E-052.00TAC1tachykinin 1NM_0093111.59E-051.77DUB2Adeubiquitinating enzyme2aNM_0010015590.0266852.28GPR6G protein-coupled receptor 6NM_19905 81.59E-051.55EGR2early growth response 2NM_0101180.0001541.66CYR61cysteine rich protein 61NM_0105160.0376711.61 Enhanced expression levels of certain genes in the cortex after chronic treatment of morphine (morphine 20 mg/kg i.p. twice daily for 9 days) in mice PCR validation of microarray-identified gene expression changes in the cortex of chronic morphine-treated mice To further validate the microarray findings, semi-quantitative PCR analysis was conducted using cortical tissues obtained from mice subjected to repeated morphine administration followed by naloxone-precipitated withdrawal. Total RNA was isolated from the frontal cortex of four individual mice per group, and gene expression levels were compared with those of saline-treated controls that underwent the same procedural conditions. Consistent with the microarray results, mRNA expression levels of Drd2, Adora2a, Gng7, Olfr767, Gpr6, and Cyr61 were significantly elevated in the chronic morphine-withdrawal group relative to controls (Fig. 2). Penk, Tac1, and Egr2 showed an increasing trend, although not significant. The direction of change was concordant with the array data, confirming that these transcriptional alterations are robustly associated with morphine exposure followed by acute withdrawal. Given that naloxone-precipitated withdrawal induces abrupt opioid receptor blockade and rapid neurochemical imbalance, the observed upregulation of Drd2 and Adora2a suggests enhanced sensitivity or compensatory adaptation within dopaminergic signaling pathways during withdrawal. Increased Penk expression may reflect activation of endogenous opioid systems in response to receptor antagonism, whereas elevated Gng7 and Gpr6 levels indicate modulation of GPCR-mediated intracellular signaling cascades. Furthermore, increased expression of the activity-dependent transcription factor Egr2 and the matricellular protein Cyr61 supports the presence of rapid transcriptional reprogramming and structural plasticity in the cortex during the withdrawal state. Together, these findings demonstrate that naloxone-precipitated withdrawal following chronic morphine administration is accompanied by coordinated and reproducible cortical gene expression changes, reinforcing the biological relevance of the microarray results and highlighting molecular adaptations associated with opioid withdrawal. Validation of cortical gene expression changes by PCR. PCR analysis of genes identified by microarray in the frontal cortex of chronic morphine-treated mice following naloxone-precipitated withdrawal. (A) Each band represents an independent mouse cortical sample and (B) Data are shown as mean ± SEM (n=4 per group). Statistical significance was assessed by unpaired two-tailed t-test: *p<0.05, **p<0.01, ***p<0.001. Gene ontology analysis of differentially expressed genes following chronic and acute morphine administration and naloxone-precipitated withdrawal To further investigate the biological significance of differentially expressed genes identified through microarray analysis, we performed gene ontology (GO) enrichment analysis. Signaling pathways associated with genes upregulated by at least 1.5-fold in the cortex of chronic and acute models were examined. Metascape analysis of these differentially expressed genes revealed significant enrichment in categories including locomotory behavior, signaling by GPCRs, the adenylate cyclase-modulating GPCR signalling pathway, neuroactive ligand-receptor interaction, translation at the presynapse, chemokine signaling pathway, and regulation of the inflammatory response (Fig. 3A). Notably, GPCR signaling showed the most pronounced increase. In the acute model, enrichment was also observed for G alpha (q) signaling events and G alpha (i) signaling events (Fig. 3B). Taken together, the overall enrichment profile suggests that morphine withdrawal induced by naloxone following chronic exposure elicits coordinated changes across GPCR-associated receptors, extracellular signaling components, and neural behavior-regulating pathways. Gene ontology (GO) enrichment analysis of genes upregulated ≥1.5-fold in the cortex of morphine-treated versus control (Con) mice. (A) Chronic model and (B) Acute model. Differentially expressed genes were analyzed using Metascape gene list analysis to identify significantly enriched biological pathways. Notably, the enrichment of intrinsic to membrane, cell surface, and GPCR protein signaling pathway categories is consistent with the upregulation of multiple receptor-related genes identified in the microarray dataset, including Drd2, Adora2a, and Gpr6. Because GPCR activation is tightly coupled to intracellular second messenger cascades that converge on cyclic adenosine monophosphate (cAMP)-dependent protein kinase A (PKA) signaling, these findings suggest that downstream transcriptional regulators may be activated during the withdrawal state. In addition, enrichment of behavior and neurological system process terms supports the involvement of activity-dependent transcriptional mechanisms underlying morphine-induced neuroadaptation. Selective activation of CREB signaling despite broad screening of stress- and neurotransmission-related targets Based on GO enrichment analysis indicating significant involvement of membrane-associated components, GPCR signaling pathways, ribosomal elements, and neurological system processes, additional downstream and stress-responsive proteins were examined to determine whether chronic morphine exposure followed by naloxone-precipitated withdrawal induced coordinated alterations at the protein level. Western blot analysis was performed to assess key regulators associated with oxidative stress responses (Nrf2, HO-1, and NQO1), molecular chaperone activity (HSP70), neuronal structural or stress-related proteins (βB1-crystallin, βB2-crystallin, and γ-crystallin), dopaminergic transmission (tyrosine hydroxylase, TH), and inhibitory neurotransmission (GAD65/67). These targets were selected based on their potential linkage to GPCR-mediated intracellular signaling, cellular stress adaptation, and neurotransmitter system remodeling during opioid withdrawal. Comprehensive screening revealed a slight decrease in the expression of βB1-crystallin and Nrf2 in the cortex compared to the saline-treated control group. No significant changes were observed in other crystallin family proteins, oxidative stress-related proteins, neurotransmitter synthase, or chaperone proteins (Fig. 4). Western blot analysis of stress- and neurotransmission-related proteins. (A, C) Western blot analysis was performed on cortical samples from individual mice (n=3 per group) to assess key proteins associated with oxidative stress, molecular chaperone activity, neuronal structure, dopaminergic transmission, inhibitory neurotransmission, and activity-dependent transcription. Quantification of western blot bands is shown on the right (B, D). Each band represents an independent mouse cortical sample. Data are shown as mean ± SEM. Statistical significance was assessed by unpaired two-tailed t-test: *p<0.05, **p<0.01. In contrast, phosphorylated CREB (pCREB) levels were strongly and statistically significantly increased in the chronic morphine withdrawal group (Fig. 4C, 4D). While no significant changes were observed in oxidative stress markers (HO-1, NQO1), neurotransmitter synthase (TH, GAD65/67), chaperone proteins (HSP70), or crystallin family proteins, the increase in pCREB was selective and consistent across independent replicates. This finding suggests that the molecular changes in the cortex during morphine withdrawal are more closely linked to the activation of specific intracellular signaling pathways than to broader changes in protein expression. Therefore, the repeatedly recapitulated pCREB increase can be interpreted as a reliable molecular correlate reflecting the withdrawal state after chronic morphine exposure and has potential significance as a key signaling marker associated with morphine-induced neuroplastic adaptation. DISCUSSION This study aimed to investigate whether both short-term and long-term morphine exposure induce alterations in neuronal gene expression. To assess the magnitude of these changes, frontal cortical gene expression in mice following acute or chronic morphine administration was monitored using cDNA microarray analysis. Microarray analysis of cDNA provides a powerful platform for identifying gene expression changes associated with disease mechanisms and potential therapeutic targets (Cherkaoui-Malki et al., 2001; Shen et al., 2019; Tan et al., 2003). In this study, we profiled cortical gene expression following acute and chronic morphine administration in C57BL/6J male mice, with particular emphasis on G protein–coupled receptor (GPCR) signaling pathways. To evaluate chronic morphine dependence in mice, the jumping test and conditioned place preference (CPP) were employed. Mice that received morphine showed a significant increase in escape jumping behavior. In the CPP assay, morphine was paired with a brightly illuminated chamber, an environment that mice innately avoid due to its anxiogenic properties. The development of a preference for this normally aversive context indicates that morphine’s rewarding effects were sufficiently strong to overcome innate avoidance behavior. Together, these findings model a key feature of human addiction, namely maladaptive reward learning in which drug-associated reinforcement overrides natural aversive responses. Microarray analysis was performed in the frontal cortex, a region undergoing long-term μ-opioid receptor–dependent neuroplastic adaptations that contribute to the cognitive and behavioral impairments underlying opioid addiction, including tolerance, dependence, and relapse (Cole et al., 2024). Among the differentially expressed genes, the upregulation of Drd2 and Adora2a is of particular interest given their well-established functional interplay. Dopamine D2 receptors and adenosine A2A receptors are known to form heteromeric complexes, especially in neuronal circuits, where they exert antagonistic modulation of intracellular signaling (Azdad et al., 2009; Ferré et al., 2018). Specifically, adenosine A2A receptor activation stimulates Gs-mediated cAMP production (González-Benítez et al., 2002; Rao et al., 2025), whereas dopamine D2 receptor signaling inhibits adenylyl cyclase via Gi/o proteins (Babenko et al., 2020; Navarro et al., 2018). The coordinated upregulation of both receptors observed in this study suggests a compensatory or adaptive mechanism aimed at fine-tuning cAMP-dependent signaling in response to repeated morphine exposure. This GPCR crosstalk is highly relevant in the context of opioid-induced neuroadaptation. Chronic morphine exposure is known to disrupt dopaminergic signaling and reward circuitry and altered Drd2 expression has been associated with maladaptive reward-seeking behaviors (Hanson et al., 2021). Concurrently, increased Adora2a expression may counterbalance dopaminergic inhibition, thereby reshaping intracellular signaling dynamics. Although the exact molecular mechanisms underlying the increased expression of Drd2 and Adora2a cannot be determined from the present data, this pattern suggests that repeated morphine exposure alters dopaminergic and adenosinergic signaling. Such bidirectional modulation may ultimately converge on downstream effectors such as cAMP response element-binding protein (CREB) (Hoffmann et al., 2012; Nishiyama et al., 2017; Ruso-Julve et al., 2019). In support of this, a selective increase in CREB phosphorylation was observed during naloxone-precipitated withdrawal. Together, these findings suggest that CREB may function as an integrative downstream node of these signaling changes, potentially contributing to neural adaptation processes that alter neuronal responsiveness to subsequent stimuli. In addition to Drd2 and Adora2a, other GPCR-related genes, including Gpr6 and Olfr767, were also upregulated, suggesting broader remodeling of receptor-mediated signaling networks (Guedj et al., 2015; Rahman et al., 2022). Olfactory receptor neuron malfunction is closely linked with disruptions of cyclic AMP-mediated intracellular signaling and neurophysiological disturbances leading to schizophrenia (Turetsky et al., 2009). It was reported that the high dose morphine-injected adult rats failed to recognize their juvenile a behavioral disorder mediated within the accessory olfactory bulb by an opioid system intrinsic to the olfactory system through μ-opioid receptors (Bianchi et al., 2013). It is quite intriguing that Olfr767 receptor, whose gene was upregulated in morphine-injected mice, and opioid receptor intrinsically may interplay and facilitate receptor desensitization culminating in morphine tolerance. The involvement of G protein subunits, such as Gng7, further supports the notion that morphine exposure induces coordinated regulation of GPCR signaling machinery. These changes likely influence receptor sensitivity, desensitization, and potential heteromerization, thereby contributing to the complexity of opioid tolerance and dependence. The observed transcriptional activation of Egr2, together with increased CREB phosphorylation, indicates that GPCR-mediated signaling alterations are tightly coupled to activity-dependent gene regulation. This linkage underscores a model in which receptor-level adaptations are translated into sustained transcriptional reprogramming during morphine exposure and withdrawal. Gene ontology analysis further supports this framework, revealing significant enrichment in membrane components, GPCR signaling pathways, and neurological system processes. Collectively, these findings suggest that morphine-induced cortical adaptations are driven by integrated changes in GPCR functional interactions—particularly between Drd2 and Adora2a—coupled with downstream second messenger systems and transcriptional regulators. In summary, our results highlight a GPCR-centered molecular network in which coordinated regulation and functional interaction of Drd2, Adora2a, and associated signaling components play a pivotal role in shaping morphine-induced neuroplasticity and behavioral dependence (Fig. 5). Elucidating the mechanistic basis of these receptor interactions will be essential for developing targeted interventions for opioid use disorders. Schematic summary of behavioral and transcriptional alterations associated with morphine dependence and withdrawal. Repeated morphine administration frequently induces both physical and psychological dependence, accompanied by alterations in frontal cortical gene expression. Our results highlight a GPCR-centered molecular network in which coordinated regulation and functional interaction of Drd2, Adora2a, and associated signaling components play a pivotal role in shaping morphine-induced neuroplasticity and behavioral dependence. These insights may provide a foundation for the development of targeted therapeutic strategies to mitigate opioid dependence. ACKNOWLEDGMENTS This study was conducted with the support of the 2023 Health Fellowship Foundation (M.K). REFERENCES